 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Washington (AFP) Jan 24, 2011 A subsidiary of the French nuclear giant Areva said Monday it had received US clearance to begin a clinical trial of an isotope that targets cancer cells. "Lead-212 is a rare radioactive isotope that lies at the heart of promising nuclear medical research to develop new cancer treatments," Areva Med said in a statement. "This innovative approach, known as alpha radio-immunotherapy, specifically pinpoints and destroys cancer cells while limiting toxicity to healthy cells." The phase one trial, which assesses safety, will begin in 2011 and take about two years. The treatment's primary target will be pancreatic cancer, a company spokesman said. "This landmark FDA authorization is a very important step that could lead to a potential treatment for very aggressive and lethal cancers," said Jacques Besnainou, CEO of Areva North America. A Food and Drug Administration spokeswoman declined to elaborate on the authorization, saying the agency does not comment on clinical trials that are under way or about to begin. Areva announced last year the construction of a facility to produce lead-212 in the Limousin region of France.
Share This Article With Planet Earth
Related Links Nuclear Power News - Nuclear Science, Nuclear Technology Powering The World in the 21st Century at Energy-Daily.com
Turkey sees political strings to France nuclear plant dealAnkara (AFP) Jan 24, 2011 Possible talks with France over the construction of a nuclear power plant in Turkey will include political considerations, Turkey's energy minister said Monday. French companies have expressed interest in the project but relations between Paris and Ankara have been soured by strong French opposition to Turkey's bid to join the European Union. "If we come to have talks with France (on a n ... read more |
|
|
| The content herein, unless otherwise known to be public domain, are Copyright 1995-2010 - SpaceDaily. AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement,agreement or approval of any opinions, statements or information provided by SpaceDaily on any Web page published or hosted by SpaceDaily. Privacy Statement |
del.icio.us
Digg
Reddit
YahooMyWeb
Google
Facebook
